Den Europæiske Union - dansk - EMA (European Medicines Agency)

shionogi b.v. - lusutrombopag - trombocytopeni - antihemorrhagics - mulpleo er indiceret til behandling af svær trombocytopeni hos voksne patienter med kronisk leversygdom, der gennemgår invasive procedurer.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - avatrombopag maleate - trombocytopeni - antihemorrhagics - doptelet er indiceret til behandling af svær trombocytopeni hos voksne patienter med kronisk leversygdom, der er planlagt til at blive en invasiv procedure. doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (itp) in adult patients who are refractory to other treatments (e. kortikosteroider, immunglobuliner).

Den Europæiske Union - dansk - EMA (European Medicines Agency)

instituto grifols s.a. - fostamatinib dinatrium - trombocytopeni - andre systemiske hemostatics - tavlesse er indiceret til behandling af kronisk immun trombocytopeni (itp) hos voksne patienter, der er refraktære over for andre behandlinger.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

amgen europe b.v. - romiplostim - purpura, trombocytopenisk, idiopatisk - antihemorrhagics - adults:nplate is indicated for the treatment of primary immune thrombocytopenia  (itp) in adult patients who are refractory to other treatments (e. kortikosteroider, immunglobuliner). paediatrics:nplate is indicated for the treatment of chronic primary immune thrombocytopenia (itp) in paediatric patients one year of age and older who are refractory to other treatments (e. kortikosteroider, immunglobuliner).

Den Europæiske Union - dansk - EMA (European Medicines Agency)

novartis europharm limited - eltrombopag - purpura, trombocytopenisk, idiopatisk - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 og 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 og 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

roche registration limited - emicizumab - hemophilia a - antihemorrhagics - hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia a (congenital factor viii deficiency):with factor viii inhibitorswithout factor viii inhibitors who have:severe disease (fviii < 1%)moderate disease (fviii ≥ 1% and ≤ 5%) with severe bleeding phenotype. hemlibra kan bruges i alle aldersgrupper.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

ecuphar veterinaria s.l.u. - etamsylat - injektionsvæske, opløsning - 125 mg/ml

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

b. braun melsungen - Æblesyre, calciumchloriddihydrat, hydroxyethylstivelse, kaliumchlorid, magnesiumchloridhexahydrat, natriumacetattrihydrat, natriumchlorid - infusionsvæske, opløsning - 60 mg/ml